Trials / Completed
CompletedNCT02912234
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is to evaluate the effects of multiple-dose clarithromycin on the single-dose pharmacokinetics (PK) of apixaban with parameters like Cmax, AUC(INF), and AUC(0-T).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | Multiple-dose clarithromycin and single-dose Apixaban |
| DRUG | Clarithromycin | Multiple-dose clarithromycin and single-dose Apixaban |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2016-10-01
- Completion
- 2016-10-01
- First posted
- 2016-09-23
- Last updated
- 2016-11-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02912234. Inclusion in this directory is not an endorsement.